Trial Profile

An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ezaladcigene resoparvovec (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Proof of concept
Acronyms AADC
Sponsors Neurocrine Biosciences; Voyager Therapeutics

Most Recent Events

14 Oct 2021 Results reporting final 36-month data from this trial published in the Neurology
16 Sep 2020 Preliminary results of three year safety and clinical outcomes presented at the 24th International Congress of Parkinsons Disease and Movement Disorders.
11 Sep 2020 According to a Neurocrine Biosciences media release, data from this study were presented today at the MDS Virtual Congress 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com